ATRA Atara Biotherapeutics, Inc.
Healthcare$9.80+4.93%ClosedMarket Cap: $88.3M
As of 2026-05-25
Valuation
P/E (TTM)
1.16
PEG
0.01
P/B
-3.70
P/S
3.82
EV/EBITDA
-16.08
DCF Value
$-460.11
FCF Yield
-29.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.1%
Operating Margin
-27.3%
Net Margin
-40.9%
ROE
25.7%
ROA
-47.3%
ROIC
-44.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $516.0K | 76.0% | $-3.4M | $-4.1M | $— | — |
| Q4 null | $1.6M | 93.5% | $-2.6M | $-3.4M | $— | — |
| FY null | $120.8M | 82.4% | $35.9M | $32.7M | $— | — |
| Q3 null | $3.5M | 96.7% | $-3.6M | $-4.3M | $— | — |
| Q2 null | $17.6M | 96.8% | $3.2M | $2.4M | $— | — |
| Q1 null | $98.1M | 79.2% | $38.8M | $38.0M | $— | — |
| Q4 null | $32.8M | 79.3% | $-12.2M | $-12.7M | $— | — |
| FY null | $128.9M | 83.7% | $-83.4M | $-85.4M | $— | — |
| Q3 null | $40.2M | 81.1% | $-21.8M | $-21.9M | $— | — |
| Q2 null | $28.6M | 83.8% | $-18.2M | $-19.0M | $— | — |
| Q1 null | $27.4M | 92.7% | $-31.2M | $-31.8M | $— | — |
| Q4 2023 | $4.3M | 25.7% | $-53.3M | $-60.5M | $-13.98 | — |